Neurocrine Biosciences, Inc. (NBIX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Neurocrine Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Neurocrine Biosciences, Inc. (NBIX) has returned -7.11% so far this year and 19.11% over the past 12 months. Over the last decade, NBIX has posted an annualized return of 12.23%, slightly higher than the S&P 500 Index benchmark’s 12.16%.

Based on dividend-adjusted daily data since May 23, 1996, NBIX's average daily return is +0.11%, while the average monthly return is +2.07%. At this rate, your investment would double in approximately 2.8 years.

Historically, 51% of months were positive and 49% were negative. The best month was Nov 1999 with a return of +91.0%, while the worst month was May 2006 at -65.6%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.

On a daily basis, NBIX closed higher 49% of trading days. The best single day was Jan 7, 2014 with a return of +89.7%, while the worst single day was May 16, 2006 at -62.0%.

Neurocrine Biosciences, Inc. has an annualized alpha of 17.52%, beta of 1.17, and R² of 0.13 versus S&P 500 Index. Calculated based on daily prices since May 24, 1996.

• This stock captured 110.81% of S&P 500 Index gains and 108.38% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.13 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NBIX ranks 58 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Neurocrine Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Neurocrine Biosciences, Inc. was 97.21%, occurring on Nov 12, 2009. Recovery took 2007 trading sessions.

The current Neurocrine Biosciences, Inc. drawdown is 15.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Neurocrine Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Neurocrine Biosciences, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.